drugset / Trial / NCT06815627
Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography
Phase 3
Active not recruiting
150 enrolled
Trust Bio-sonics, Inc.
CMIC ASIA-PACIFIC, PTE. LTD., TAIWAN BRANCH · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This is a Phase 3, prospective, open-label, multicenter study to assess the efficacy of NH002-enhanced echocardiography in subjects with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the left ventricular endocardial border delineation compared with unenhanced echocardiography. The study also aims to investigate the safety and tolerability of NH002.
Timeline
- Start
- 2025-03-18
- Primary completion
- 2027-02
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NH002 | Diagnostic / imaging agent | 2.5 unknown | Intravenous |